Tonghua Dongbao Pharmaceutical Co Ltd Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd asset resilience ratio. Tonghua Dongbao Pharmaceutical Co Ltd (600867) has an Asset Resilience Ratio of 0.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Tonghua Dongbao Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tonghua Dongbao Pharmaceutical Co Ltd (2016–2025)
Asset resilience ratio of Tonghua Dongbao Pharmaceutical Co Ltd from 2016 to 2025. This chart shows how Tonghua Dongbao Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 600867 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tonghua Dongbao Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tonghua Dongbao Pharmaceutical Co Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥63.00 Million | 0.76% |
| Total Liquid Assets | CN¥63.00 Million | 0.76% |
Asset Resilience Insights
- Limited Liquidity: Tonghua Dongbao Pharmaceutical Co Ltd maintains only 0.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tonghua Dongbao Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tonghua Dongbao Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Tonghua Dongbao Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2016–2025)
Tonghua Dongbao Pharmaceutical Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Tonghua Dongbao Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.80% | CN¥63.22 Million ≈ $9.25 Million |
CN¥7.91 Billion ≈ $1.16 Billion |
+0.05pp |
| 2024-12-31 | 0.75% | CN¥55.40 Million ≈ $8.11 Million |
CN¥7.38 Billion ≈ $1.08 Billion |
+0.04pp |
| 2023-12-31 | 0.71% | CN¥55.52 Million ≈ $8.12 Million |
CN¥7.77 Billion ≈ $1.14 Billion |
-0.15pp |
| 2022-12-31 | 0.87% | CN¥58.46 Million ≈ $8.55 Million |
CN¥6.75 Billion ≈ $987.78 Million |
+0.30pp |
| 2021-12-31 | 0.57% | CN¥37.00 Million ≈ $5.41 Million |
CN¥6.52 Billion ≈ $954.10 Million |
-2.02pp |
| 2020-12-31 | 2.59% | CN¥150.37 Million ≈ $22.00 Million |
CN¥5.80 Billion ≈ $849.20 Million |
-3.32pp |
| 2018-12-31 | 5.91% | CN¥323.00 Million ≈ $47.27 Million |
CN¥5.46 Billion ≈ $799.46 Million |
-0.65pp |
| 2017-12-31 | 6.56% | CN¥312.00 Million ≈ $45.66 Million |
CN¥4.75 Billion ≈ $695.47 Million |
-1.99pp |
| 2016-12-31 | 8.56% | CN¥400.00 Million ≈ $58.53 Million |
CN¥4.68 Billion ≈ $684.10 Million |
-- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more